The
Briscoe Law Firm, PLLC, founded by a former state prosecutor and
enforcement attorney for the United States Securities and Exchange
Commission, and the securities law firm of Powers
Taylor, LLP are investigating potential legal claims against the
officers and Board of Directors of Medifast, Inc. ("Medifast” or "MED”)
(NYSE: MED) during the period of March 4, 2010 through March 10, 2011
(the "Class Period”).
It has been alleged in a recently-filed class action complaint that
during the Class Period, Medifast and certain of its officers and
directors made materially false and misleading statements or failed to
disclose material information related to the Medifast’s business and
operations in violation of the Securities Exchange Act of 1934.
Specifically, it is alleged that the defendants failed to disclose: (1)
that Medifast was improperly recognizing certain expenses; (2) that the
company lacked adequate internal and financial controls; and (3) that,
as a result of the foregoing, Medifast’s financial results were
materially false and misleading at all relevant times. On March 11,
2011, when Medifast disclosed that it was delaying filing its fiscal
2010 financial results and annual report, the company’s stock declined
$5.27 per share, or nearly 25%.
If you currently own or purchased Medifast/MED shares and would like
additional information regarding this investigation or if you have
information regarding the allegations against the company, please
contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607,
via e-mail at patrick@powerstaylor.com,
or Willie Briscoe at The Briscoe Law Firm, PLLC toll free (877)
397-5991, or via email at WBriscoe@TheBriscoeLawFirm.com.
There is no cost or fee to you.
The Briscoe Law Firm is a full service business litigation, commercial
transaction, and public advocacy firm with more than 20 years of
experience in complex litigation and transactional matters.
Powers Taylor, LLP is a boutique litigation law firm that handles a
variety of complex business litigation matters, including claims of
investor and stockholder fraud, shareholder oppression, shareholder
derivative suits, and security class actions.
